S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:VERA

Vera Therapeutics - VERA Stock Forecast, Price & News

$16.35
-0.35 (-2.10%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.73
$16.74
50-Day Range
$15.74
$22.19
52-Week Range
$12.28
$34.64
Volume
95,752 shs
Average Volume
131,072 shs
Market Capitalization
$452.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.33

Vera Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.1% Upside
$35.33 Price Target
Short Interest
Bearish
15.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.36mentions of Vera Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.59 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.08) to ($3.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

889th out of 1,047 stocks

Pharmaceutical Preparations Industry

431st out of 512 stocks

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031
See More Headlines
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Company Calendar

Last Earnings
11/10/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VERA
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.33
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+116.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.82 per share

Miscellaneous

Free Float
15,737,000
Market Cap
$452.24 million
Optionable
Not Optionable
Beta
0.10

Key Executives

  • Dr. Marshall Fordyce M.D.Dr. Marshall Fordyce M.D. (Age 48)
    Founder, Pres, CEO & Director
    Comp: $715.36k
  • Mr. Sean P. Grant M.B.A. (Age 37)
    Chief Financial Officer
    Comp: $506.83k
  • Dr. Celia Lin M.D. (Age 47)
    Chief Medical Officer
    Comp: $645.82k
  • Mr. Joseph R. Young M.B.A. (Age 49)
    Sr. VP of Fin. & Chief Accounting Officer
  • Dr. Tad Thomas Ph.D. (Age 61)
    Sr. VP and Head of Product Devel. & Manufacturing
  • Mr. Tom Doan (Age 50)
    Sr. VP of Devel. Operations
  • Ms. Lauren Frenz (Age 37)
    Chief Bus. Officer
  • Dr. Joanne Curley Ph.D. (Age 53)
    Chief Devel. Officer













VERA Stock - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERA shares.
View VERA analyst ratings
or view top-rated stocks.

What is Vera Therapeutics' stock price forecast for 2023?

4 brokerages have issued 12-month price objectives for Vera Therapeutics' shares. Their VERA share price forecasts range from $32.00 to $38.00. On average, they predict the company's stock price to reach $35.33 in the next year. This suggests a possible upside of 116.1% from the stock's current price.
View analysts price targets for VERA
or view top-rated stocks among Wall Street analysts.

How have VERA shares performed in 2022?

Vera Therapeutics' stock was trading at $26.72 on January 1st, 2022. Since then, VERA shares have decreased by 38.8% and is now trading at $16.35.
View the best growth stocks for 2022 here
.

Are investors shorting Vera Therapeutics?

Vera Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,050,000 shares, an increase of 15.8% from the October 31st total of 1,770,000 shares. Based on an average daily trading volume, of 108,500 shares, the days-to-cover ratio is currently 18.9 days. Approximately 15.5% of the shares of the stock are short sold.
View Vera Therapeutics' Short Interest
.

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our VERA earnings forecast
.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.33.

When did Vera Therapeutics IPO?

(VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Vera Therapeutics' stock symbol?

Vera Therapeutics trades on the NASDAQ under the ticker symbol "VERA."

Who are Vera Therapeutics' major shareholders?

Vera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Citadel Advisors LLC (7.36%), Kynam Capital Management LP (5.67%), BlackRock Inc. (2.92%), Vanguard Group Inc. (2.80%), Polar Asset Management Partners Inc. (1.93%) and Alphabet Inc. (1.11%). Insiders that own company stock include Carlyle Group Inc, Joanne Curley, Llp Abingworth, Marshall Fordyce, Patrick G Enright, Sean Grant and Sofinnova Venture Partners X,.
View institutional ownership trends
.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vera Therapeutics' stock price today?

One share of VERA stock can currently be purchased for approximately $16.35.

How much money does Vera Therapeutics make?

Vera Therapeutics (NASDAQ:VERA) has a market capitalization of $452.21 million. The company earns $-32,610,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How can I contact Vera Therapeutics?

The official website for the company is veratx.com. The company can be reached via phone at 650-770-0077 or via email at ir@veratx.com.

This page (NASDAQ:VERA) was last updated on 12/2/2022 by MarketBeat.com Staff